Keyphrases
Adverse Events
28%
Amgen
7%
Binding Antibodies
7%
Calcitonin Gene-related Peptide
7%
Calcitonin Receptor
7%
Chronic Migraine
100%
Clinical Laboratory
7%
Clinical Research Center
7%
Clinically Significant
7%
Efficacy Analysis
7%
Erenumab
100%
Headache
7%
Headache Days
7%
Injection Pain
7%
Laboratory Results
7%
Laboratory Values
7%
Long-term Efficacy
7%
Long-term Safety
7%
Migraine Days
7%
Migraine Pathophysiology
7%
Monoclonal Antibody
7%
Monthly Migraine Days
21%
Nausea
7%
Neutralizing Antibodies
7%
North America
7%
North Europe
7%
One Dose
14%
Patient Study
7%
Phase II Trial
100%
Placebo
50%
Placebo-controlled
100%
Potential Therapy
7%
Preventive Treatment
100%
Randomized Double-blind
100%
Response System
7%
Safety Analysis
7%
Safety Endpoints
7%
Safety Profile
7%
Serious Adverse Events
7%
Treatment Assignment
7%
Upper Respiratory Tract Infection
7%
Vital Signs
14%
Voice User Interface
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
35%
Calcitonin Gene Related Peptide
7%
Calcitonin Gene Related Peptide Receptor
7%
Clinical Research
7%
Headache
14%
Human Monoclonal Antibody
7%
Injection Site Pain
7%
Migraine
42%
Nausea
7%
Neutralizing Antibody
7%
Pathophysiology
7%
Placebo
100%
Transformed Migraine
100%
Upper Respiratory Tract Infection
7%